Clinical Study Confirms Effectiveness of Medical Marijuana, Inc.’s RSHO — CFN Media

SEATTLE, WA–(Marketwired – Mar 15, 2017) – CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering a clinical study of RSHO-X, Medical Marijuana Inc. (OTC PINK: MJNA) subsidiary HempMeds Mexico’s flagship hemp based cannabidiol oil.

Cannabidiol (CBD), the main ingredient in RSHO-X, has been growing in popularity due to its tremendous potential to treat many serious medical conditions. In fact, the cannabinoid has shown promise in treating everything from arthritis to antibiotic resistant infections to schizophrenia. The non-psychoactive nature of the compound also means that it is subject to less regulatory scrutiny than tetrahydrocannabinol (THC) and may be provided both over-the-counter and as a prescription.

Medical Marijuana recently announced the results of a study evaluating the safety and effectiveness of RSHO-X 5000 for the treatment of Lennox Gastaut Syndrome — a severe form of childhood encephalopathies with high seizure frequency, progressive cognitive impairment, and antiepileptic drug resistance. The condition affects roughly 30,000 individuals in the United States and another 300,000 individuals around the world.

The study found that RSHO-X 5000 reduced motor seizures for 84% of patients, with more than half of participants reporting a better than 75% reduction in seizures. In addition, 17% of patients reported a complete elimination of all seizures. The study also found an 89% improvement in quality of life, like alertness (43%), social interaction (40%) and attention (30%) with no reported adverse side effects to the 5-7mg of CBD per kilogram of bodyweight.

Medical Marijuana has relied on external evidence to support the import of its RSHO products into countries like Brazil, Mexico, and Puerto Rico for specific medical conditions. While there are numerous studies supporting the use of CBDs, clinical studies involving the company’s own RSHO product lines could provide even more support for importation, since mainstream doctors in these countries and territories may be more willing to prescribe the drug.

To view the study, follow the link:

Please follow the link to read the full article:

Learn how to become a CFN Media featured company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

About Medical Marijuana Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

CFN Media
Frank Lane
[email protected]